PCA
REGN icon

Peddock Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Peddock Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-55
Closed -$23K – 205
2019
Q1 		$23K Hold
55
– – 0.01% 194
2018
Q4 		$21K Hold
55
– – 0.01% 198
2018
Q3 		$22K Hold
55
– – 0.01% 203
2018
Q2 		$19K Hold
55
– – 0.01% 206
2018
Q1 		$19K Hold
55
– – 0.01% 205
2017
Q4 		$21K Hold
55
– – 0.01% 200
2017
Q3 		$25K Hold
55
– – 0.01% 193
2017
Q2 		$27K Buy
+55
New +$24.1K 0.01% 196

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Peddock Capital Advisors's REGN Position: Q2 2019 in Review

Peddock Capital Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2019, closing a stake of 55 shares — an estimated $23K sold.

Peddock Capital Advisors first reported a position in REGN in Q2 2017 and held it in 8 quarters. The position peaked at $27K in Q2 2017. 658 funds tracked by Wall St. Rank hold REGN as of Q2 2019.

  • Peddock Capital Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Peddock Capital Advisors sold 55 Regeneron Pharmaceuticals shares in Q2 2019, an estimated $23K.
  • Peddock Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2017 and held it in 8 quarters.
  • Peddock Capital Advisors's Regeneron Pharmaceuticals position peaked at $27K in Q2 2017.
  • 658 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2019.

Based on Peddock Capital Advisors's 13F filing for Q2 2019, filed 6 Aug 2019.